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Open access under the Elsbstract
he aim of this study was to deﬁne factors that inﬂuence therapy outcome of submandibular botulinum
xin injections for drooling in children with cerebral palsy or mental disability. We postulated that
ifferences in response may be explained by the variation of dysfunctions in the various cerebral palsy
subtypes. Prospectively collected data were evaluated of 80 spastic and 48 dyskinetic children, of whom
70% had an IQ of <70. In addition, the data of 23 fully ambulant children with mental disability only were
examined. Flow and Drooling Quotient were assessed at baseline and at 8 weeks after injection. After
treatment, both the Drooling Quotient and submandibular ﬂow decreased in all children. Morbidity
associated with the procedure was limited. Ninety-three children responded to botulinum. Decrease of
submandibular ﬂow in these childrenwas associated with reduction of parotid ﬂow. In those who did not
respond to therapy, spread across all 3 diagnostic classiﬁcations, parotid ﬂow increased after injection.
Response failure is characterized by increased parotid ﬂow after injection; however, the precise role of
parotid ﬂow in therapy failure remains unclear. We cannot predict who will respond to botulinum toxin
to treat drooling.
 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Drooling is normal in the growing child up to the age of 18
months. Beyond the age of 4 years, it is abnormal and frequently
persists in children with poor neuromuscular coordination, in chil-
dren with mental disabilities, and in children who lack structural
integrity in their jaws, lips, or oral cavity [1]. It is widely accepted
that drooling in cerebral palsy is caused by oral motor dysfunction
[2-5]. An exception to this may be for those with dyskinetic disor-
ders,where the abnormal oralmovementsmayconstantly stimulate
the parotid glands to produce more saliva [2]. Moreover, the risk of
oromotor disorders and excessive drooling increases inwheelchair-
bound persons and in children with any degree of intellectual
impairment [6]. The inadequate swallowing of saliva may increase
the risk of aspiration and may contribute to impaired communica-
tion as a result of the constant presence of saliva.us; Department of Pediatric
entre; PO Box 9101; Internal
s.
evier OA license.In several prospective, controlled clinical trials, signiﬁcant
reduction of saliva with a maximum response at 2 to 8 weeks
was found after botulinum toxin type A injection [7]. Botulinum
toxin inhibits the acetylcholine release at the autonomic termi-
nals of the salivary glands, decreasing the secretion of water.
However, after 10 years’ experience in our multidisciplinary
drooling clinic, it was observed that up to 30% of children,
drooling severity and frequency did not greatly change after
submandibular botulinum toxin A injection. In our previous
study, we suggested that increased saliva production due to
constant stimulation of the parotid glands resulting from
hyperkinetic oral movements might account for drooling in those
with dyskinetic disorders [2]. In addition, peripheral sympathetic
inhibition of salivary reﬂex secretion has been described as being
related to nonphysiologic conditionsdfor instance, after botu-
linum toxin application [8]. To evaluate these possibilities, we
performed the present cohort study to explore the effect of
submandibular botulinum toxin type A on the parotid salivary
ﬂow in 3 distinct clinical groups: children with spastic cerebral
palsy, children with dyskinetic cerebral palsy, and children with
mental disability without cerebral palsy. We hypothesized that
C.E. Erasmus et al. / Pediatric Neurology 45 (2011) 95e9996treatment efﬁcacy would be similar across all 3 groups with
similar rates of responsiveness.
In view of the anticholinergic property of botulinum toxin, it is
likely that the watery component of saliva will be reduced and
that after receipt of botulinum toxin, the salivary viscoelasticity
increases [9]. Interestingly, it has been reported that saliva viscosity
reduces after botulinum toxin injections [10]. The opposite
phenomenon (much thinner salivary aspect after receipt of botu-
linum toxin) may indicate that the reﬂex salivary secretion from
other salivary glands increases after submandibular botulinum
toxin type A; therefore, we hypothized that nonresponsiveness to
submandibular botulinum type A may be caused by compensatory
parotid ﬂow.Table 1. Clinical characteristics
Characteristic Spastic CP Dyskinetic CP Mental Disability
without CP
No. of patients 62/126 (49%) 45/126 (36%) 19/126 (15%)
Affected side Quadriplegic 58,
hemiplegic 4
Bilateral
affected
Not applicable
Age, mean (S.D.) 11 y 4 mo
(4 y 5 mo)
10 y 2 mo (5 y) 11 y (6 y 4 mo)
Sex (M/F) 43/19 27/18 11/8
DA
<4 y 34 (55%) 22 (49%) 15 (79%)
4-6 y, IQ <70 11 (18%) 9 (20%) 0 (0%)
4-6 y, IQ >70 2 (3%) 1 (2%) 0 (0%)
>6 y 15 (24%) 13 (29%) 4 (21%)
GMFCS* All ambulatory
I 0 (0%) 0 (0%)
II 6 (10%) 2 (4%)
III 21 (34%) 6 (13%)
IV 18 (29%) 19 (42%)
V 17 (27%) 18 (40%)
Abbreviations:
CP ¼ Cerebral palsy
DA ¼ Developmental age
GMFCS ¼ Gross Motor Functional Classiﬁcation System
* Signiﬁcantly different between the 3 groups by Kruskal-Wallis test.Patients and Methods
Patients
We analyzed data from 126 individuals (aged 3-21 years, mean age 10 years and
11 months, standard deviation 4 years and 11 months; 81 male and 45 female
patients) who were screened at the outpatient drooling clinic of the Radboud
University Nijmegen Medical Center, The Netherlands, and who had undergone
treatment with an injection of botulinum toxin type A into the submandibular
glands between February 2000 and October 2008. Children were categorized as
having cerebral palsy or mental disability on the basis of developmental age [11] and
the severity of motor disturbances as assessed by the Gross Motor Function Classi-
ﬁcation System [12,13]. The children with cerebral palsy were subdivided by the
predominant motor type [14]. All of the children demonstrated moderate to severe
dysfunctional oral motor control and had a score of 3 or higher on the Teacher
Drooling Scale (a 5-point scale to express the clinical severity and frequency of
drooling; 5 ¼ constantly wet and leaking saliva, 1 ¼ no drooling) [15]. None had
undergone previous treatment with botulinum toxin type A or surgery for saliva
control.
For the statistical analyses, the following classiﬁcations were used: ﬁrst, inves-
tigation of the inﬂuence of 3 categories (spastic cerebral palsy subtype, dyskinetic
cerebral palsy subtype, and mental disability not classiﬁed within the cerebral palsy
group), and second, exploration of the differences within the cerebral palsy group
(the 2 cerebral palsy subtypes). All medications used to treat drooling or to inﬂuence
salivary secretion (especially benzodiazepines and neuroleptic drugs) were
discontinued at least 3 months before the start of the treatment. No limits were set
concerning the use of antiepileptic drugs and the child’s level of cognitive devel-
opment. Data from children diagnosed with ataxic cerebral palsy subtype, Worster-
Drought syndrome, or a progressive neurologic condition were excluded from the
study. The research was conducted in accordance with national and international
ethics standards, and the Regional Committee on Research Involving Human
Subjects approved the study. Informed consent was obtained from the parents or
caregivers of all the study children.
An ultrasound-guided injection of botulinum toxin type A was injected bilat-
erally into the submandibular salivary glands divided over 2 sites per gland with
a 25-gauge needle (Spinocan). A total dose of 50 U of Botox (Allergan, Nieuwegein,
The Netherlands), diluted with 1.5 mL saline, was used. Drooling intensity and
salivary ﬂow were measured at baseline and at 8 weeks after injection. Drooling
intensity was evaluated by the Drooling Quotient, a semiquantitative observational
method (expressed as a percentage) representing the actual clinical appearance of
saliva loss. The Drooling Quotient was scored according to the original design:
drooling was evaluated during a 10-minute episode. A drooling episode was
deﬁned as new saliva present on the lip margin or dropping from the chin. The
presence or absence of drooling was assessed every 15 seconds (40 observations in
10 minutes) [16].
To measure the salivary ﬂow rate, we used the swab method, as follows. After
the oral cavity had been dried with sterile gauze, 3 absorbent dental cotton rolls
(Salivette; Sarstedt, Etten-Leur, The Netherlands) were placed in the mouth for
periods of 5 minutes: 1 roll under the tongue directly in front of the oriﬁces of the
submandibular and sublingual glands, and 2 rolls in the upper vestibules at the
openings of the parotid ducts [17]. Two well-trained speech and language thera-
pists conducted all the assessments, which always took place in the morning, 1
hour after the last meal. The cotton rolls were weighed before and after the
procedure with an electronic scale, which is sensitive to 0.01 g. The roll under the
tongue and the 2 upper vestibules rolls were weighted separately, to be deﬁned as
submandibular and parotid ﬂow. The increase in weight during the 5-minute
period was converted into milliliters of saliva per minute to determine salivary
ﬂow rate.
At each assessment, the medical history was taken, especially regarding feeding,
speech, coughing, and salivary aspects [18]. In addition, the parents were asked to
register all possible side effects in a diary.Data analysis
Baseline evaluation
Data analysis included descriptive statistics, the median salivary ﬂow rates, and
themedian Drooling Quotient. Themedian salivary ﬂow rates and Drooling Quotient
were compared between the 3 categories by nonparametric statistics (Kruskal-
Wallis and Mann-Whitney U tests) because of nonnormal distribution of these
measures. Missing datawere rare but on occasionwere adjusted by the overall mean
of the group.
Therapy response
Multivariable analyses of variance (MANOVA) with a repeated measures struc-
ture were used to identify differences in mean submandibular and parotid ﬂow and
Drooling Quotient across time using baseline and 8 weeks’ assessment as variables.
In addition, when either of the analyses had a signiﬁcant effect, a post hoc test was
performed to determine the differences between the groups. Because we wanted to
control for the type I error rate, the Bonferroni adjustment for multiple comparison
was used.
Therapy failure and clinical variables
A successful therapy responsewas deﬁned as 30% submandibular ﬂow reduction
and/or 50% reduction of the Drooling Quotient. The 30% demand has been previously
reported and is explained by the estimated measurement error of the swab method
to evaluate the salivary ﬂow rate [17]. A 50% reduction in the Drooling Quotient
reﬂected a clinically relevant change [7]. The submandibular glands produce about
60-70% of baseline salivary ﬂow. In the event the Drooling Quotient is reduced by
50% after botulinum toxin injections, the change of ﬂow from the submandibular
glands, being the only gland exposed to this intervention, must have added
substantially to this reduction. All participants were categorized as responding to or
not responding to submandibular botulinum toxin type A. MANOVAwith a repeated
measures structure was used to identify differences in the mean parotid ﬂow
between the responding and the nonresponding groups. In addition, for each group
(responsive or unresponsive to botulinum toxin type A), we computed the Spear-
man’s correlation coefﬁcient to deﬁne the magnitude of the associations between
spastic or dyskinetic cerebral palsy subtype, mental disability, mobility level, and
treatment response. For all statistics, the level of signiﬁcance for 2-tailed P values
was set at 0.05. All statistical procedures were carried out by SSPS 17.0 for
Windows (SPSS, Chicago, IL).
Results
Table 1 lists the patients’ clinical characteristics. All children
completed treatment. There was no signiﬁcant difference in
the baseline demographic variables between the groups, with the
exception of mobility. The mobility level differed between the
children with mental disability and the total cerebral palsy group
(U ¼ 196.00; P < 0.001) and also between the children with spastic
and dyskinetic cerebral palsy subtype (U ¼ 1038.00; P ¼ 0.02).
Table 2. Median Drooling Quotient and salivary ﬂow rate differences (range) in
time between each group
Drooling Parameter Spastic CP Dyskinetic CP Mental Disability
without CP
Sm0, mL/min 0.39 (0.08-0.68) 0.38 (0.06-1.09) 0.36 (0.16-0.48)
Par0, mL/min 0.32 (0.0-1.06) 0.36 (0.04-1.25) 0.24 (0.04-0.94)
DQ0, % 22.5 (0.0-80.0)* 32.5 (0.0-97.5)* 27.5 (0.0-77.5)
Sm8, mL/min 0.22 (0.02-0.85) 0.26 (0.04-0.48) 0.20 (0.04-0.8)
Par8, mL/min 0.27 (0.0-1.12) 0.27 (0.0-0.61) 0.22 (0.0-0.68)
DQ8, % 16.9 (0.0-65.0) 12.5 (0.0-57.5) 15.0 (0.0-27.5)
Abbreviations:
CP ¼ Cerebral palsy
Sm0, Par0, DQ0 ¼ Median submandibular and parotid ﬂow and Drooling Quotient
at baseline
Sm8, Par8, DQ8 ¼ Median submandibular and parotid ﬂow and Drooling Quotient
at 8-wk assessment
* Signiﬁcant difference for median Drooling Quotient at baseline between
children with spastic and with dyskinetic CP (P ¼ 0.03, Mann-Whitney U test).
Table 4. Characteristics of children who did or did not respond to botulinum
toxin type A
All Patients
(n ¼ 126)
Response
(n ¼ 93)
No Response
(n ¼ 33)
Spastic CP* 44/62 (71%) 18/62 (29%)
Dyskinetic CP 35/45 (78%) 10/45 (22%)
Mental disability
without CP
14/19 (74%) 5/19 (26%)
Age, mean (S.D.) 11 y 1 mo (5 y 6 mo) 10 y 4 mo (4 y 8 mo)
Sex (M/F) 61/32 20/13
DA
<4 y* 52 (56%) 19 (58%)
4-6 y, IQ <70 18 (19%) 2 (6%)
4-6 y, IQ >70 2 (2%) 1 (3%)
>6 y 21 (23%) 11(33%)
Sm0, mL/min (range) 0.42 (0.06-1.09) 0.34 (0.08-0.60)
Par0, mL/miny (range) 0.38 (0.04-1.25) 0.20 (0.0-1.06)
DQ0, % (range) 28.1 (0.0-97.5) 22.5 (0.0-80.0)
Sm8, mL/min (range) 0.18 (0.02-0.54) 0.28 (0.12-0.85)
Par8, mL/min (range) 0.27 (0.0-0.86) 0.27 (0.04-1.12)
DQ8, % (range) 12.5 (0.0-57.5) 17.5 (2.5-65.0)
Abbreviations:
DA ¼ Developmental age
Sm0, Par0, DQ0 ¼ Median submandibular and parotid ﬂow and Drooling Quotient
at baseline
Sm8, Par8, DQ8 ¼ Median submandibular and parotid ﬂow and Drooling Quotient
at 8-wk assessment point
* Nonsigniﬁcant by Spearman’s correlation coefﬁcient.
y P ¼ 0.02.
C.E. Erasmus et al. / Pediatric Neurology 45 (2011) 95e99 97Because of limitations related to the clinical diagnoses, it was not
always possible to obtain simultaneous scores for the swab tests
and the Drooling Quotient at 1 measurement session. The swab
testing at baseline could be performed in 109 children and in 100
children at the 8-week assessment. At baseline, the Drooling
Quotient was determined in 120 children and at 8 weeks in 109
children. Missing data (14%) occurred at different assessment
moments randomly spread over all children. Data of the median
submandibular and parotid ﬂow rates, and Drooling Quotient at
baseline and at 8 weeks after injection of all participants are listed
in Table 2. Table 3 provides the results between the diagnosis
categories at baseline and after submandibular botulinum toxin
type A therapy.
According to our deﬁnition, 93 children responded fully and 33
children were unresponsive to botulinum toxin type A (Table 4). At
baseline, there were neither statistically signiﬁcant differences
between the median submandibular ﬂow rate (U ¼ 1189.50; P ¼
0.06) nor the median Drooling Quotient (U ¼ 1302.50; P ¼ 0.20),
whereas the difference for the median parotid ﬂow rate was
statistically signiﬁcant (U ¼ 1099.00; P ¼ 0.02) between the chil-
dren responsive or unresponsive to botulinum toxin type A.
Furthermore, in the children responsive to botulinum toxin type A,
decrease of submandibular ﬂow rate across time was accompanied
with decrease of parotid ﬂow, whereas in children unresponsive to
botulinum toxin type A, the parotid ﬂow rate increased marginally.Table 3. Results between diagnostic categories
Patient Group Baseline P Therapy Response P
Statistics Statistics
Spastic vs dyskinetic
CP subtype vs mental
disability without CP
DQ H(2) ¼ 4.96 0.08 F(2; 123) ¼ 2.59 0.08
Sm H(2) ¼ 0.46 0.79 F(2; 123) ¼ 0.44 0.65
Par H(2) ¼ 0.58 0.75 F(2; 123) ¼ 4.67 0.01*
Spastic vs dyskinetic
CP subtype
DQ U ¼ 1053.00; 0.03 F(1; 105) ¼ 5.01 0.03
Sm U ¼ 1343.00 0.74 F(1; 105) ¼ 0.60 0.44
Par U ¼ 1274.00 0.44 F(1; 105) ¼ 8.97 0.01y
Abbreviations:
CP ¼ Cerebral palsy
DQ ¼ Drooling Quotient
Par ¼ Parotid ﬂow
Sm ¼ Submandibular ﬂow
* Nonsigniﬁcant by post hoc test.
y Nonsigniﬁcant by test of between-subject effects.The difference in the parotid ﬂow rates over time was statistically
signiﬁcant (F(1;124) ¼ 20.92; P < 0.001) between the those who
did and did not respond to therapy. The median parotid ﬂow rates
across time between children responsive and unresponsive to
botulinum toxin type A are presented in Figure 1. Clinical variables
as developmental age (rs ¼ 0.03; P ¼ 0.71), mobility level (rs ¼
0.08; P ¼ 0.38), and spastic or dyskinetic cerebral palsy (rs ¼ 0.08;
P ¼ 0.43) did not signiﬁcantly correlate with response percentage.
Although injections were usually well tolerated, there were
several minor side effects in this series (Table 5).Discussion
This prospective study suggests that submandibular botulinum
toxin type A treatment for drooling has similar effects across
severely affected children with spastic or dyskinetic cerebral palsy,
and for those with mental disability without cerebral palsy. The
data did not support the phenomenon of increased salivary ﬂow
resulting from mechanical stimulation of salivary glands in dyski-
netic cerebral palsy. However, the ﬁndings did suggest that drool-
ing is clinically distinct between children with spastic and
dyskinetic cerebral palsy. Although increased salivary parotid ﬂow
rates in children unresponsive to submandibular botulinum toxin
type A were found, the role of parotid ﬂow in therapy failure could
not be settled in the current study. Therapy failure might mainly be
explained by factors that inﬂuence the intraoral management of
saliva, such as head position, lip closure, and disturbed oral
movements instead of biological factors such as neurologic regu-
latory mechanisms of salivary ﬂow.
As generally discussed in the cerebral palsy literature, the rate of
mental disability and dyskinesia increases as functionality
decreases. Against this background, we concluded that our group
represented not an average group of children with cerebral palsy,
but a very severely affected group [19,20].
The overall percentage of children who responded (74%) was in
accordance with the ﬁndings of a former study (70%) [7,21].
Figure 1. Median parotid ﬂow rate in time between children who did and did not respond to therapy with botulinum toxin type A. Diamonds indicate response (n ¼ 97); boxes
indicate no response (n ¼ 33). X-axis ¼ assessment points: 1 ¼ at baseline, 2 ¼ at 8 weeks after injection; y-axis ¼ median parotid ﬂow rate (mL/min).
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method we used is possible, the mean imputation method never-
theless provided unbiased estimates in current study because the
missing values met the strong assumption of being missing
completely at random [22].
Earlier we suggested that in children with dyskinetic disorders,
drooling might be caused by increased production of saliva
resulting from constant stimulation of the parotid glands. In the
present study, we were unable to demonstrate this outcome. A
possible explanation could be that the swab method technique
itself plays a role. The position of the cottons rolls limited move-
ments of the jaw and tongue considerably (“ﬁxed mouth”),
hindering potential salivary gland stimulation in children with
dyskinetic cerebral palsy during the assessments. The increased
drooling intensity in dyskinetic cerebral palsy assessed by the
Drooling Quotient observation, where voluntary oral motor func-
tion was still possible (“dynamic mouth”), suggested that
mechanical stimulation of the salivary glands might contribute to
drooling in the dyskinetic cerebral palsy subtype. Furthermore, the
children with dyskinetic cerebral palsy seemed to have better
residual swallowing functions, as explained by the clear decrease of
the Drooling Quotient after submandibular botulinum application.
The clinical response failure was approximately 26% in our
study. Because ultrasound was used, incorrect application of
botulinum toxin type A would not be likely as a reason for the
observed therapy failure. Adequate doses were used, and response
failure due to antibody formation to the ﬁrst botulinum toxin type
A application can be considered to be irrelevant. Moreover, it wasTable 5. Adverse effects after botulinum toxin type A at 8-week assessment
Adverse Effect Spastic CP
(n ¼ 62)
Dys
(n ¼
R NR R
Increased salivary viscosity 9/62 (15%) 2/62 (3%) 16/
Reduced salivary viscosity 1/62 (2%) 0/62 (0%) 1/
Problems swallowing 2/62 (3%) 2/62 (3%) 2/
Increased frequency
of pulmonary infections
3/62 (5%) 2/62 (3%) 1/
Speech problems 1/62 (2%) 1/62 (2%) 0/
Dry mouth 0/62 (0%) 0/62 (0%) 1/
Oral odor 0/62 (0%) 0/62 (0%) 0/
Abbreviations:
CP ¼ Cerebral palsy
NR ¼ No response to botulinum toxin type A
R ¼ Response to botulinum toxin type Aunlikely that chemical diffusion of the toxin via local vasculature or
by the inﬂuence of gravity caused the parotid ﬂow to decrease
because none of the participants experienced bulbar muscle
weakness [23].
One possible explanation for the observed therapy failure might
be the inadequate inhibition of the reﬂex arc of salivary secretion
after botulinum toxin application. Saliva secretion is a nerve-
mediated reﬂex, and once the autonomic nerve supplydin partic-
ular the parasympathetic nerve supplydhas been interrupted,
secretion from almost all salivary glands will entirely cease [24]. It
is understood that under normal conditions, inhibition of reﬂex
salivary secretion is centrally controlled. However, under non-
physiologic conditions, for instance after botulinum toxin applica-
tion, peripheral sympathetic inhibition of salivary secretion comes
into action [8]. It might be possible that the concept of insufﬁcient
peripheral sympathetic inhibition of the salivary secretion did play
a role in unresponsiveness to botulinum toxin. Another explanation
for response failure may be the contribution of factors related to
handling of saliva. An earlier study revealed that the response rate
cannot be improved by simply injecting the submandibular and
parotid glands concurrently [25]. Moreover, in the present study, it
was observed that the response to submandibular botulinum toxin
type A changes according to the deﬁnition of good clinical response.
Because the deﬁnition of response was deﬁned as a 30% subman-
dibular ﬂow reduction (“biological factor”), the size of the effect
decreased from 76% to 65% and even to 47% if response was deﬁned
as a 50% reduction of Drooling Quotient (linked to the ability to
control saliva). Therefore, it might well be that factors relatedkinetic CP
45)
Mental Disability without CP
(n ¼ 19)
NR R NR
45 (36%) 3/45 (6%) 1/19 (5%) 0/19 (0%)
45 (2%) 0/45 (0%) 0/19 (0%) 0/19 (0%)
45 (4%) 0/45 (0%) 0/19 (0%) 2/19 (11%)
45 (2%) 0/45 (0%) 0/19 (0%) 0/19 (0%)
45 (0%) 0/45 (0%) 0/19 (0%) 0/19 (0%)
45 (2%) 1/45 (2%) 0/19 (0%) 0/19 (0%)
45 (0%) 0/45 (0%) 1/19 (5%) 0/19 (0%)
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to therapy failure.
We remain unable to predict which patient will respond to
botulinum toxin type A. Moreover, univariate parameters such as
motor impairment (“quality of movement”), mobility level and
mental ability (“functional ability”), and even baseline Drooling
Quotient and ﬂow rates had no decisive value in discriminating
between therapy response or nonresponse in this study. Remark-
ably, before injection, an important difference in the parotid ﬂow
rates was found between the childrenwho did and did not respond
to botulinum toxin type A (Fig 1). However, we are not able to
explain the pathophysiology of the difference.
An disadvantage of the present study might be the omission of
measuring the caregivers’ perception of treatment effectiveness
[26,27]. However, we particularly wanted to focus on factors that
might affect the saliva-control intervention, rather than evaluating
the overall effectiveness of the intervention.
In conclusion, there were arguments for increased salivary ﬂow
due to hyperkinetic oral movements in dyskinetic cerebral palsy,
and probably the children with dyskinetic cerebral palsy might
have better residual swallowing functions. However, the efﬁcacy of
submandibular botulinum toxin type A to treat drooling in chil-
dren with cerebral palsy subtypes or with mental disability
without cerebral palsy appeared to be similar. Future research is
needed to provide tools to predict who will respond to therapy
and to settle the matter of the contribution of parotid ﬂow in
response failure.
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